Viral infections and immune modulation in bladder cancer: implications for immunotherapy
- PMID: 40291982
- PMCID: PMC12022759
- DOI: 10.37349/etat.2025.1002311
Viral infections and immune modulation in bladder cancer: implications for immunotherapy
Abstract
This review explores the intricate relationship between viral infections and Bacillus Calmette-Guerin (BCG) efficacy, emphasizing immune modulation mechanisms that may influence treatment outcomes. Since its introduction in 1976, intravesical BCG has been a cornerstone in managing non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumors (TURBT). Despite its success, variability in response rates suggests that host immune status, influenced by persistent infections, immunosenescence, and antigenic overload, may play a crucial role in therapeutic effectiveness. Chronic viral infections can modulate T cell responses, leading to immune exhaustion and impaired antitumor immunity. This review discusses the interplay between viral antigenic load, immune dysfunction, and tumor microenvironment remodeling, highlighting their potential impact on immunotherapies. By integrating insights from virome analysis, immune profiling, and tumor characterization, this review proposes personalized strategies to enhance immunotherapy efficacy. A deeper understanding of viral-induced immune dysregulation may improve prognostic assessment, optimize treatment protocols, and reduce healthcare costs associated with bladder cancer. Future research should focus on targeted interventions to mitigate the immunosuppressive effects of chronic infections, ultimately improving patient outcomes in NMIBC management.
Keywords: Virome; exhaustion; immune response; senescence; urothelial carcinoma.
© The Author(s) 2025.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures

Similar articles
-
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8. Future Oncol. 2024. PMID: 38189180
-
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.J Med Econ. 2023 Jan-Dec;26(1):411-421. doi: 10.1080/13696998.2023.2189860. J Med Econ. 2023. PMID: 36897006
-
Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.Clin Nutr. 2021 Dec;40(12):5792-5801. doi: 10.1016/j.clnu.2021.10.019. Epub 2021 Nov 1. Clin Nutr. 2021. PMID: 34775222
-
Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue "Seminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma".Urol Oncol. 2023 Oct;41(10):398-409. doi: 10.1016/j.urolonc.2022.05.013. Epub 2022 Jul 8. Urol Oncol. 2023. PMID: 35811207 Free PMC article. Review.
-
Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guérin immunotherapy: a systematic review and meta-analysis.Front Immunol. 2024 Oct 23;15:1464635. doi: 10.3389/fimmu.2024.1464635. eCollection 2024. Front Immunol. 2024. PMID: 39507536 Free PMC article.
References
-
- Bladder Cancer Stages [Internet] National Cancer Institute; [cited 2025 Mar 15]. Available from: https://www.cancer.gov/types/bladder/stages#_26 .
Publication types
LinkOut - more resources
Full Text Sources